Table 3 Correlation between TBS and GC cumulative dose with different serum bone markers in the whole group of patients, in the lGC group and hGC group
| Â | All patients (N = 47) | Low GC group (N = 22) | High GC group | |||
|---|---|---|---|---|---|---|
Variable | TBS | Cumulative GC dose | TBS | Cumulative GC dose | TBS | Cumulative GC dose |
TBS | – |  | – |  | – |  |
Cumulative dose GC | − 0.19 (ns) | – | 0.003 (ns) | – | − 0.4 (p = 0.048) | – |
DKK | − 0.86 (p < 0.0001) | 0.12(ns) | − 0.82 (p < 0.0001) | 0.62 | − 0.9 (p < 0.0001) | 0.42 (p = 0.033) |
Sclerostin | − 0.43 (p = 0.003) | 0.32 (p = 0.026) | − 0.58 (p = 0.004) | 0.07 (ns) | − 0.47 (p = 0.04) | 0.16 (ns) |
RANK-L | − 0.76 (p < 0.001) | 0.14 (ns) | − 0.75 (p < 0.0001) | 0.54 (ns) | − 0.71 (p < 0.0001) | 0.22 (ns) |
OPG | 0.43 (p = 0.002) | − 0.37 (p = 0.009) | 0.38 (ns) | − 0.9 (ns) | 0.45 (p = 0.023) | − 0.33 (ns) |
OPG/RANK-L | 0.76 (p < 0.0001) | − 0.23 (ns) | 0.78 (p < 0.0001) | − 0.11 (ns | 0.74 (p < 0.0001) | − 0.32 (ns) |